EyePoint Pharmaceuticals, Vizient to distribute drug to manage eye inflammation


Biopharmaceutical company EyePoint Pharmaceuticals has entered into a partnership with supply group purchasing organization Vizient to offer its postoperative inflammation drug dexycu to Vizient's customers.

The partnership began Nov. 1. Vizient customers, which includes 50 percent of acute care providers and 20 percent of ambulatory providers, will receive the drug at a discount. The partnership is slated to last three years.

"Since the launch of dexycu in the first quarter of this year, EyePoint’s dedicated sales team has been making consistent headway in penetrating targeted ambulatory surgical centers to deliver Dexycu to patients who can benefit from the product’s differentiated profile and efficacy," said Nancy Lurker, president and CEO of EyePoint Pharmaceuticals.

More articles on supply chain:
Medline, HOTB Software Solutions partner to ease accreditation process
ASC software providers collaborate to improve integration, interoperability — 4 things to know
Delaware gastroenterology practice adds Drs. Vineet Gudsoorkar, Shruti Patel — 3 insights

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers